Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study - PubMed (original) (raw)
doi: 10.1016/S1470-2045(07)70042-6.
Kai Yan, Feng Lin, Keith Anderson, Christos Sotiriou, Fabrice Andre, Frankie A Holmes, Vicente Valero, Daniel Booser, John E Pippen Jr, Svetislava Vukelja, Henry Gomez, Jaime Mejia, Luis J Barajas, Kenneth R Hess, Nour Sneige, Gabriel N Hortobagyi, Lajos Pusztai, W Fraser Symmans
Affiliations
- PMID: 17329190
- DOI: 10.1016/S1470-2045(07)70042-6
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
Yun Gong et al. Lancet Oncol. 2007 Mar.
Abstract
Background: Gene expression microarrays are being used to develop new prognostic and predictive tests for breast cancer, and might be used at the same time to confirm oestrogen-receptor status and ERBB2 status. Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling.
Methods: We used gene expression data of 495 breast cancer samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical status of these genes (as established by immunohistochemical [IHC] or fluorescence in-situ hybridisation [FISH], or both). Data from 195 fine-needle aspiration (FNA) samples were used to define mRNA cutoff values that assign receptor status. We assessed the accuracy of these cutoffs in two independent datasets: 123 FNA samples and 177 tissue samples (ie, resected or core-needle biopsied tissues). Profiling was done at two institutions by use of the same platform (Affymetrix U133A GeneChip). All data were uniformly normalised with dCHIP software.
Findings: ESR1 and ERBB2 mRNA levels correlated closely with routine measurements for receptor status in all three datasets. Spearman's correlation coefficients ranged from 0.62 to 0.77. An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accuracy of 90% (training set), 88% (first validation set), and 96% (second validation set). An ERBB2 mRNA threshold of 1150 identified ERBB2-positive status with the overall accuracy of 93% (training set), 89% (first validation set), and 90% (second validation set). Reproducibility of mRNA measurements in 34 replicate experiments was high (correlation coefficient 0.975 for ESR1, 0.984 for ERBB2).
Interpretation: Amounts of ESR1 and ERBB2 mRNA as measured by the Affymetrix GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively.
Comment in
- Quantitative measures of oestrogen receptor and ERBB2 expression.
Hayes DF. Hayes DF. Lancet Oncol. 2007 Mar;8(3):184-5. doi: 10.1016/S1470-2045(07)70050-5. Lancet Oncol. 2007. PMID: 17329185 No abstract available.
Similar articles
- Identification and validation of an ERBB2 gene expression signature in breast cancers.
Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adélaïde J, Geneix J, Bachelart L, Finetti P, Koki A, Hermitte F, Hassoun J, Debono S, Viens P, Fert V, Jacquemier J, Birnbaum D. Bertucci F, et al. Oncogene. 2004 Apr 1;23(14):2564-75. doi: 10.1038/sj.onc.1207361. Oncogene. 2004. PMID: 14743203 - The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
Du X, Li XQ, Li L, Xu YY, Feng YM. Du X, et al. Breast Cancer Res Treat. 2013 Feb;138(1):59-67. doi: 10.1007/s10549-013-2432-2. Epub 2013 Feb 10. Breast Cancer Res Treat. 2013. PMID: 23397283 - Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A. Rody A, et al. Zentralbl Gynakol. 2006 Apr;128(2):76-81. doi: 10.1055/s-2006-921508. Zentralbl Gynakol. 2006. PMID: 16673249 Clinical Trial. - Oestrogen receptor variants and mutations in human breast cancer.
Murphy LC, Leygue E, Dotzlaw H, Douglas D, Coutts A, Watson PH. Murphy LC, et al. Ann Med. 1997 Jun;29(3):221-34. doi: 10.3109/07853899708999340. Ann Med. 1997. PMID: 9240628 Review.
Cited by
- Investigation of recurrence prediction ability of EndoPredict® using microarray data from fresh frozen tissues in ER-positive, HER2-negative breast cancer and indication expansion of EndoPredict® from microarray data from fresh-frozen to FFPE tissues.
Watanabe A, Tsunashima R, Kato C, Kitano S, Matsumoto S, Sota Y, Morita M, Sakaguchi K, Naoi Y. Watanabe A, et al. Breast Cancer. 2024 Jul;31(4):593-606. doi: 10.1007/s12282-024-01573-7. Epub 2024 Apr 8. Breast Cancer. 2024. PMID: 38587783 - Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
Lin HK, Can T, Kahn A, Flannery CA, Hoag J, Akkunuri A, Bailey H, Baehner R, Pusztai L, Rozenblit M. Lin HK, et al. Oncologist. 2023 Oct 3;28(10):e973-e976. doi: 10.1093/oncolo/oyad249. Oncologist. 2023. PMID: 37656608 Free PMC article. - Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, Ducoulombier A, Pistilli B, Bachelot T, Viret F, Levy C, Signolle N, Alfaro A, Tran DTN, Garberis IJ, Talbot H, Christodoulidis S, Vakalopoulou M, Droin N, Stourm A, Kobayashi M, Kakegawa T, Lacroix L, Saulnier P, Job B, Deloger M, Jimenez M, Mahier C, Baris V, Laplante P, Kannouche P, Marty V, Lacroix-Triki M, Diéras V, André F. Mosele F, et al. Nat Med. 2023 Aug;29(8):2110-2120. doi: 10.1038/s41591-023-02478-2. Epub 2023 Jul 24. Nat Med. 2023. PMID: 37488289 Free PMC article. Clinical Trial. - Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer.
Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam M, Tan AW, Mughees M, Vidhu F, Liu DD, Taliaferro JM, Pitner MK, Browning LS, Lee JH, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere SJ, Bartholomeusz G, Dalby KN, Bartholomeusz C. Xie X, et al. Cancer Res Commun. 2023 Jun 20;3(6):1078-1092. doi: 10.1158/2767-9764.CRC-22-0330. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37377604 Free PMC article. - The potential of mRNA expression evaluation in predicting HER2 positivity in gastroesophageal cancer.
Oliveira IM, Nicolau-Neto P, Fernandes PV, Lavigne TS, Neves PF, Tobar JC, Soares-Lima SC, Simão TA, Pinto LFR. Oliveira IM, et al. Braz J Med Biol Res. 2022 Nov 11;55:e12428. doi: 10.1590/1414-431X2022e12428. eCollection 2022. Braz J Med Biol Res. 2022. PMID: 36383805 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous